Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Aging (NIA) |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00743327 |
The purpose of this study is to examine the link between low testosterone and insulin resistance/diabetes in men undergoing androgen deprivation therapy for prostate cancer. The study will also evaluate other cardiovascular risk factors in these men.
Condition | Intervention |
---|---|
Hypogonadism Metabolic Syndrome Diabetes Inflammation |
Drug: Pioglitazone |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Metabolic and Cardiovascular Complications in Men With Prostate Cancer Undergoing Long-Term Androgen Deprivation Therapy |
Serum, Muscle biopsy specimens
Estimated Enrollment: | 60 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | October 2010 |
Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
1
Participants receiving ADT and pioglitazone
|
Drug: Pioglitazone
45mg capsule, once daily for 1 year
|
2
Participants receiving ADT only
|
|
3
Participants not receiving ADT and in remission from prostate cancer
|
Lowering of testosterone levels, by medications or surgery (Androgen Deprivation Therapy or ADT), is commonly used in the treatment of prostate cancer. The adverse effects of low testosterone include decreased sex drive, impotence, decreased lean body mass and muscle strength, increased fat mass, decreased quality of life and osteoporosis.
An increase in body fat and decrease in lean body mass may contribute to a decrease in the body's ability to use insulin effectively, leading to insulin resistance and diabetes. Low testosterone levels are also associated with elevated total cholesterol, LDL-cholesterol and triglycerides.
Two groups of non-diabetic men will be studied:
The non-ADT group and half of the ADT group will be observed for the development of insulin resistance/diabetes. The other half of the ADT group will receive a diabetes medication called Pioglitazone (Actos) to evaluate any beneficial effects of this medication in the prevention of metabolic dysfunction.
The study will consist of a screening visit and 6 additional study visits throughout one year. Procedures during this study include blood draws, MRI, CT, DEXA scan, insulin clamp procedures, oral glucose tolerance tests, carotid IMT, pulse wave velocity, neuropsychological testing, physical exams and an optional muscle biopsy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Community sample of men ages 18 and older with prostate cancer
Inclusion Criteria:
Exclusion Criteria:
Contact: Denise Melvin, RN | 410-350-3924 | melvinde@grc.nia.nih.gov |
Contact: Recruiter, National Institute on Aging at Harbor Hospital | 410-350-3941 | NIAStudiesRecruitment@mail.nih.gov |
United States, Maryland | |
National Institute on Aging / Clinical Research Branch | |
Baltimore, Maryland, United States, 21225 |
Principal Investigator: | Josephine M. Egan, MD | National Institute on Aging, Intramural Research Program |
Responsible Party: | National Institute on Aging, Intramural Research Program ( Josephine M. Egan, MD ) |
Study ID Numbers: | AG0107 |
Study First Received: | August 26, 2008 |
Last Updated: | August 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00743327 |
Health Authority: | United States: Federal Government |
hormone therapy |
Hypogonadism Pioglitazone Gonadal Disorders Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Prostatic Neoplasms Inflammation |
Hypoglycemic Agents Disease Pathologic Processes |
Syndrome Physiological Effects of Drugs Pharmacologic Actions |